A phase II study of antiangiogenic therapy (Apatinib) plus chemotherapy as second‐line treatment in advanced small cell lung cancer

INTRODUCTION: Currently, only a few options are available for the treatment of patients with small‐cell lung cancer (SCLC) after the failure of first‐line platinum‐based chemotherapy. The present study aimed to evaluate the efficacy and safety of apatinib plus chemotherapy for second‐line treatment...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Yinghui, Wang, Xu, Sun, Chao, Gao, Zhiru, He, Hua, Qiu, Shi, Guo, Ye, Ma, Xiaohui, Song, Junya, Ma, Kewei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939110/
https://www.ncbi.nlm.nih.gov/pubmed/36082491
http://dx.doi.org/10.1002/cam4.5217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9939110/
https://www.ncbi.nlm.nih.gov/pubmed/36082491
http://dx.doi.org/10.1002/cam4.5217

Ejemplares similares